The most significant prostate diseases (PD) are benign prostatic hyperplasia (BPH), prostatic intraepithelial neoplasia (PIN) and prostate cancer (PC). Generally, all PD are rare before the age of 50 with growing number of patients, primarily with BHP, with each next decade, but about decade later the highest number of PIN and PC began to report. The aim of this paper is to examine some of clinical, biochemical and histopathological characteristics of BPH, PIN and PC. Our sample consisted of 169 men. Statisticaly the most common PD was BPH-77.5%, and the rarest PIN-8.3% (p<0.001). The average age of patients was 70.6±7.5 years (51-89) with no significant differences between diagnosis (p=0.415). PIN and PC are more often found in people from urban areas (p=0.004). In the central prostate area BPH is significantly higher in 88.5% (p<0.001). Peripheral parts are significantly more common places of PIN and PC (p<0.001). Median serum PSA values is statistically highest in PC-87.2 ng/ml (12.7-372.5), (p<0,001), especially those with predominantly peripheral parts localization. Gleason score is an important prognostic factor, with average value at PC is 7.32±1.4 (5-10), with a significantly higher values for diffuse PC. BPH is the most common, and PIN rarest PD. All diseases have occurred in people older than 50 years. Usually, BPH is in central and PIN and PC in peripheral prostate parts. PSA values were highest at PC, which is a prove of its importance in malignancy early detection.
Abrahamsson PA, Falkner S, Falt K, Grimelius L. The course of neuroendocrine differentiation in prostatic carcinomas: an immunohistochemical study testing chromogranin A as an “endocrine marker.” Vol. 185, Pathol Res Pract. p. 373–80.
2.
Baisden BL, Kahane H, Epstein JI. Perineural invasion, mucinous fibroplasia, and glomerulations: diagnostic features of limited cancer on prostate needle biopsy. Vol. 23, Am J Surg Pathol. p. 918–24.
3.
Beahrs OH, Henson DE, Hutter RP, Kennedy BJ. American Joint Committee on Cancer staging manual for staging of cancer.
4.
Bostwick DG, Amin MB, Dundore P, Marsh W, Schultz DS. Architectural patterns of high-grade prostatic intraepithelial neoplasia. Vol. 24, Hum Pathol. p. 298–310.
5.
Bostwick DG, Grignon DJ, Hammond ME, Amin MB, Cohen M, Crawford D, et al. Prognostic factors in prostate cancer. Vol. 124, Arch Pathol Lab Med. p. 995–1000.
6.
Bostwick DG, Qian J. High-grade prostatic intraepithelial neoplasia. Vol. 17, Mod Pathol. p. 360–79.
7.
Bumbaširević V, Lačković V, Milićević NM, Milićevic Ž, Mujović S, Obradović M, et al. Medicinski fakultet.
8.
Catalona WJ, Smith DS, Wolfert RL. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. Vol. 274, JAMA. p. 1214–20.
9.
Cook PJ, Doll R, Fellingham SA. A mathematical model for the age distribution of cancer in man. Vol. 4, Int J Cancer. p. 93–112.
10.
Edge S, Byrd DR, Compton CC. American Joint Committee on Cancer staging manual.
11.
Epstein JI, Murphy WM. Diseases of the prostate gland and seminal vesicles. In: Urological Pathology. p. 148–241.
Gartner IP, Hiatt JL. Color textbook of Histology.
14.
Ghani KR, Grigor K, Tulloch DN, Bollina PR, McNeill SA. Trends in Reporting Gleason Score 1991 to 2001: Changes in the Pathologist’s Practice. Vol. 45, Eur Urol. p. 196–201.
15.
Gleason DF. Histologic grading of prostate cancer: a perspective. Vol. 3, Hum Pathol. p. 273–9.
16.
In: Globocan 2012 (IARC), Section of Cancer Surveillance.
17.
Greene DR, Wheeler TM, Egawa S, Weaver RP, Scardino PT. Relationship between clinical stage and histological zone of origin in early prostate cancer: morphometric analysis. Vol. 68, Br J Urol. p. 499–509.
18.
Humphrey PA. Gleason grading and prognostic factors in carcinoma of the prostate. Vol. 17, Mod Pathol. p. 292–306.
19.
Institut za javno zdravlje Srbije “Dr Milan Jovanović Batut”. Incidencija i mortalitet od raka u Centralnoj Srbiji 2012, Registar za rak u Centralnoj Srbiji izveštaj br. 14.
20.
Jemal A, Siegel R, Xu J, statistics WEC.
21.
Krušlin B, Tomas D, Rogatsch H, Novosel I, Čupić H, Belicza M, et al. Periacinar clefting in the prostatic needle core biopsies: an important diagnostic criterion or a simple artifact? Vol. 443, Virchows Arch. p. 524–7.
22.
Krušlin B, Tomas D, Čviko A, Čupić H, Odak LJ, Belicza M. Periacinar clefting and P63 immunostaining in prostatic intraepithelial neoplasia and prostatic carcinoma. Vol. 12, Pathol Oncol Res. p. 205–9.
23.
McNeal JE, Price HM, Redwine EA, Freiha FS, Stamey TA. Stage A versus stage B adenocarcinoma of the prostate: morphological comparison and biological significance. Vol. 139, J Urol. p. 61–5.
24.
McNeal JE, Redwine EA, Freiha FS, Stamey TA. Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Vol. 12, Am J Surg Pathol. p. 897–906.
25.
Mijović M, Vukićević D, Mitić N, Kneževic M, Đerković B. Periacinarne pukotine u adenokarcinomu prostate, prostaticnoj intraepitelnoj neoplaziji i benignoj hiperplaziji prostate. Vol. 38, Praxis Medica. p. 1–7.
26.
Mijović M, Vukićević D, Đerković B, Nedeljković V, Vitković L. Značaj periacinusnih pukotina kao pomoćnog dijagnostičkog kriterijuma u dijagnozi adenokarcinoma prostate Gleason score-a 7 (3+4) i Gleason score-a 7 (4+3) i njihov odnos prema parametrima od prediktivnog značaja. Vol. 43, Praxis Medica. p. 59–69.
27.
Mijovic M, Corac A, Smiljic S, Savic S, Mandic P, Vitkovic L, et al. Correlation of focal neuroendocrine differentiation in prostate cancer with the parameters of predictive value. Vol. 76, Vojnosanitetski pregled. 2019. p. 1115–26.
28.
Mijović M, Vukićević D, Đerković B, Nedeljković V, Vitković L. Prognostički značaj Gleason score-a 7 (3+4) i Gleason score-a 7 (4+3) u adenokarcinomu prostate u odnosu na klinički stadijum, tkivni androgen status i stepen neuroendokrine diferencijacije. Vol. 43, Praxis Medica. p. 1–12.
29.
Mijović M, Vukićević D, Đerković B, Savić S, Vitković L, Nedeljković V. Specifičnost i senzitivnost preoperativnih vrednosti ukupnog serumskog prostata specifičnog antigena u dijagnostici najčešćih patohistoloških promena prostate. Vol. 46, Praxis Medica. p. 7–19.
30.
Mijović M. Fokalna neuroendokrina diferencijacija adenokarcinoma prostate u korelaciji sa histološkim gradusom, kliničkim stadijumom i preoperativnim vrednostima serumskog prostata specifičnog antigena. Doktorske disertacije, Priština, Kosovska Mitrovica.
31.
Moore CK, Karikehalli S, Nazeer T, Fisher HA, RP K, Mian BM. Prognostic significance of high grade prostatic intraepithelial neoplasia and atypical small proliferation in the contemporary era. Vol. 173, J Urol. p. 70–2.
32.
O’Dowd GJ, Veltri RW, Miller MC, Strum SB. The Gleason score: a significant biological manifestation of prostate cancer aggressiveness on biopsy. Vols. 4, Vol. 1, PCRInsights.
33.
Parker C, Gillessen S, Heidenreich A, Horwich A. ESMO Guidelines Committee. Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Vol. 26, Ann Oncol.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
